[Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].
OBJECTIVE
Data for quality of care and health economics in patients with occupationally acquired hepatitis C are lacking in Germany. The aim of this study was to analyse quality and economics of health care in occupationally acquired hepatitis C recognized by the Employees Compensation Boards between 1993 and 2000 in the area of Cologne and Bochum, Germany.


METHODS
Results for 192 patients (146 women and 46 men, mean age 42 +/- 10 years) were analysed, using a standardized evaluation form. In addition to direct medical costs and diagnostic and therapeutic performance, disability days and benefit payments were also analysed. The observational period was from 01.01.1993 to 31.07.2004. Disability benefits were considered from 1983 onwards.


RESULTS
HCV genotype 1 accounted for 79 % of infections. 112 patients (58 %) received antiviral treatment at least once. There were no differences in treatment rates between patients with prognostically favorable genotypes (2/3) and those with unfavorable HCV types (1/4) (59 % v. 60 %) or patients with low and those with advanced fibrosis (61 % v. 64 %). A sustained virological response was achieved in 53 % of treated patients. Disability days were more frequent in patients receiving antiviral treatment (214 v. 67 days). The cost of medication made up a major part of health care expenditure (mean of i 13,279 per patient). In addition, total disability benefits of i 6,933,789 were paid out between 1983 and 2004.


CONCLUSIONS
Occupationally acquired hepatitis C is a major health-economic burden in Germany. Quality of health care corresponded to guidelines at any one time and sustained virological response was in the range of large controlled trials. However, 69 % of the patients remain chronically infected and are at risk for disease progression and transmission.
Reiser
M
M
Ruhr-Universität Bochum, Abt. Gastroenterologie-Hepatologie, BG-Kliniken Bergmannsheil und Medizinische Klinik Knappschaftskrankenhaus Bochum, Germany. m.reiser@paracelsus-klinik-marl.de
Haverkamp
A
A
Dintsios
M
M
Mölleken
C
C
Krauth
C
C
Pieper
W
W
Schmiegel
W
W
D000328:Adult; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D017281:Cost of Illness; D018450:Disease Progression; D005260:Female; D005838:Genotype; D005858:Germany; D017048:Health Care Costs; D016174:Hepacivirus / Q000145:classification / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D008297:Male; D009784:Occupational Diseases / Q000188:drug therapy / Q000191:economics*; D011787:Quality of Health Care
D000998:Antiviral Agents